Patient Characteristics
| Characteristic | Evaluable patients for baseline assessment (n = 156) | Evaluable patients for response assessment (n = 67) |
| Median baseline age (y) | 68 (range, 62–77) | 70 (range, 64–77) |
| Median baseline PSA (ng/mL) | 189 (range, 0.67–6,359) | 159 (range, 0.67–1,425) |
| Median baseline ALP (U/L) | 2.9 (range, 0.19–28.6) | 2.9 (range, 0.19–20.3) |
| Median baseline aBSI | 4.5 (range, 0.01–22.4) | 4.0 (range, 0.01–19.7) |
| Metastasis to bone (n) | 156 (100%) | 91 (100%) |
| Deaths (n) | 104 (56%) | 39 (58%) |
| 223Ra doses (n) | 5 (1–6) | 5 (1–6) |